Abstract
Abstract Engineered adoptive cell therapies redirect and augment the ability of immune effector cells to mount an anti-tumor response by introducing novel capabilities and targeting moieties. A prominent example of this approach is the use of T cells engineered to express chimeric antigen receptors (CARs), which have demonstrated significant efficacy against some hematologic malignancies. However, despite sophisticated strategies to harness immune cell function, CAR T cell efficacy against solid tumors has remained disappointing. Macrophages have recently emerged as prominent candidate effector cells for the treatment of solid tumors. Macrophages are innate immune cells that are intrinsically equipped with broad therapeutic effector functions, including homing to tumor sites, phagocytosis, activation of the tumor microenvironment and antigen presentation. In this presentation we will discuss strategies for genetic manipulation of CAR macrophages, illustrated by preclinical results. Citation Format: Saar Gill. Chimeric antigen receptor macrophages for the treatment of solid tumors [abstract]. In: Abstracts: AACR Virtual Special Conference: Tumor Immunology and Immunotherapy; 2021 Oct 5-6. Philadelphia (PA): AACR; Cancer Immunol Res 2022;10(1 Suppl):Abstract nr IA06.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
